.png){kind=icon}
返回
Fondaparinux sodium
.png){kind=icon}
PRE
AI
DOI：10.2165/00003495-200262110-00007.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Fondaparinux sodium, a selective factor Xa inhibitor, is the first in a new class of antithrombotics. It binds selectively with high affinity to antithrombin III and specifically catalyses the inactivation of factor Xa. The elimination half-life of fondaparinux sodium permits once daily treatment. A randomised, double-blind, parallel-group, dose-ranging, multicentre phase IIb study in 933 eligible patients established that a subcutaneous dose of between 1.5 and 3mg of fondaparinux sodium has the optimum efficacy and safety profile for prophylaxis of venous thromboembolism in patients undergoing major orthopaedic surgery. Fondaparinux sodium, given to more than 3600 patients undergoing major orthopaedic surgery who participated in prospective, randomised, double-blind, multicentre phase III clinical trials, significantly reduced the incidence of venous thromboembolism, with an overall risk reduction of 55.2% compared with enoxaparin. Fondaparinux sodium was well tolerated by patients undergoing major orthopaedic surgery, and at the recommended clinical dose of 2.5mg has a similar tolerability profile, including bleeding events, to standard enoxaparin regimens. Fondaparinux sodium has not been reported to cause antibody-induced thrombocytopenia.
Keyword:
FACTOR-XA INHIBITOR
HIP-REPLACEMENT SURGERY
RISK-ASSESSMENT MODELS
DEEP-VEIN THROMBOSIS
SYNTHETIC PENTASACCHARIDE
VENOUS THROMBOEMBOLISM
PHARMACOLOGICAL-PROPERTIES
ORTHOPEDIC-SURGERY
ANTITHROMBIN-III
POSTOPERATIVE FONDAPARINUX
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
暂无机构信息
引用论文
Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide开发合成肝素五糖的生化和药理学原理.png)
THROMBOSIS RESEARCH
THROMBOSIS RESEARCHIF3.4
PREAI
分享收藏A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
OAAI
OAAI分享收藏Biochemical and pharmacological properties of SANORG 32701 - Comparison with the 'synthetic pentasaccharide' (SR 90107 ORG 31540) and standard heparinCIRCULATION RESEARCH
CIRCULATION RESEARCHIF16.2
PREAI
分享收藏分享收藏
查看更多内容